Survival-Assured Liver Injury Preconditioning (SALIC) Enables Robust Expansion of Human Hepatocytes in \( \text{Fah}^{-/-}\text{-Rag2}^{-/-}\text{-IL2rg}^{-/-} \) Rats

Ludi Zhang, Jian-Yun Ge, Yun-Wen Zheng,* Zhen Sun, Chenhua Wang, Zhaoliang Peng, Baihua Wu, Mei Fang, Kinji Furuya, Xiaolong Ma, Yanjiao Shao, Nobuhiro Ohkohchi, Tatsuya Oda, Jianglin Fan, Guoyu Pan, Dali Li,* and Lijian Hui*

Although liver-humanized animals are desirable tools for drug development and expansion of human hepatocytes in large quantities, their development is restricted to mice. In animals larger than mice, a precondition for efficient liver humanization remains preliminary because of different xeno-repopulation kinetics in livers of larger sizes. Since rats are ten times larger than mice and widely used in pharmacological studies, liver-humanized rats are more preferable. Here, \( \text{Fah}^{-/-}\text{-Rag2}^{-/-}\text{-IL2rg}^{-/-} \) (FRG) rats are generated by CRISPR/Cas9, showing accelerated liver failure and lagged liver xeno-repopulation compared to FRG mice. A survival-assured liver injury preconditioning (SALIC) protocol, which consists of retorsine pretreatment and cycling 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) administration by defined concentrations and time intervals, is developed to reduce the mortality of FRG rats and induce a regenerative microenvironment for xeno-repopulation. Human hepatocyte repopulation is boosted to \( 31 \pm 4\% \) in rat livers at 7 months after transplantation, equivalent to approximately a 1200-fold expansion. Human liver features of transcriptome and zonation are reproduced in humanized rats. Remarkably, they provide sufficient samples for the pharmacokinetic profiling of human-specific metabolites. This model is thus preferred for pharmacological studies and human hepatocyte production. SALIC may also be informative to hepatocyte transplantation in other large-sized species.

1. Introduction

The liver is a vital organ for the metabolism and clearance of drugs. Complete features of the liver in a particular species cannot be fully recapitulated in any other species, mainly reflected from their metabolism specificities. Humanized liver in mice was thus successfully achieved by transplanting primary human hepatocytes (PHHs) to livers of immunodeficient mice after xeno-repopulation induced by liver injury.[1,2] As a model system, this mouse model with humanized liver was applied on human drug metabolism and hepatitis virus infection.[3] In addition, liver xeno-repopulation in immunodeficient mice was considered for in vivo expansion of human hepatocytes to be used for regenerative medicine.[3,4] It is noteworthy that liver-humanized animals with a human hepatocyte xeno-repopulation level >30% are required for most applications.[3] The high level of human hepatocyte chimerism in mice, achieved through decades of methodological improvements, leads to many expectations for future pharmacological and clinical applications.[6–9] However,
because of size limitations, mice cannot provide sufficient amounts of biological samples for pharmacological analyses or human hepatocytes for potential regenerative medicines.\(^\text{10}\) Hence, animals larger than mice, such as rats and pigs, have been actively studied to generate new models of humanized livers.\(^\text{3}\)

Compared with mice, rats are at least ten times larger in size. In theory, one rat liver can produce up to 1 billion human hepatocytes if xenorepulation is complete in the liver. Rats are also similar to humans in terms of many physiological and pathological aspects.\(^\text{11}\) They are recommended as the first choice for studying drug metabolism and toxicology.\(^\text{12}\) Importantly, many conclusive decisions are based solely on pharmacokinetic analyses using rats during drug discovery.\(^\text{13}\) On the other hand, when compared with pigs, rats have the advantage to breed into severe immunodeficiency for xenotransplantation.\(^\text{14}\)

Recent advances in the liver humanization of rats have not yet met the expectations for pharmacological and clinical applications. A major roadblock is the low efficiency of xenorepulation of transplanted human hepatocytes in recipient rats. To achieve high xenorepulation, it is necessary to develop an optimized precondition for human hepatocyte transplantation in rats. Previously, preconditioning with retrorsine, a pyrrolizidine alkaloid that specifically inhibits mitosis of rat hepatocytes, enabled the engraftment of PHHs in immunosuppressed rats. However, retrorsine pretreatment alone only led to scattered repopulation below 1%.\(^\text{15}\) In our recent study, the combination of retrorsine pretreatment and partial hepatectomy promoted xenorepulation in \(\text{Rag}^{1/-}\) rats.\(^\text{16}\) Nevertheless, in all reported studies, the xenorepulation of human hepatocytes has not reached 5% using retrorsine-based preconditioning.\(^\text{17}\)

Fumarylacetoacetate hydrolase (Fah)-deficiency, a model of tyrosinemia Type I, has been demonstrated as one of the most successful preconditionings in mice, in which liver injury was induced by withdrawing the protective drug 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC).\(^\text{18}\) We and other groups had generated a rat model of \(\text{Fah}\) gene knockout (\(\text{Fah}^{-/-}\)).\(^\text{19,20}\) In which NTBC withdrawal-induced liver injury drove repopulation to a level up to 90% after syngeneic transplantation of wild-type rat hepatocytes.\(^\text{19}\) However, with complete NTBC withdrawal, 40% \(\text{Fah}^{-/-}\) rat recipients died after hepatocyte transplantation because of acute liver failure.\(^\text{19}\) By contrast, almost all \(\text{Fah}^{-/-}\) mouse recipients survived after transplantation of syngeneic hepatocytes.\(^\text{21}\) These findings highlighted a remarkable difference in injury responses between \(\text{Fah}\)-deficient rats and mice. Moreover, compared to mice, transplanted human hepatocytes displayed lagged xenorepulation kinetics in rats, which could be partially attributed to larger liver size.\(^\text{22}\) Together, all these differences implicated the potential difficulty of xenorepulation of PHHs in \(\text{Fah}^{1/-}\) rats. It is apparent that strategies used for mice ought to be optimized substantially for the development of humanized liver in rats.

Here, we generated severely immunodeficient \(\text{Fah}^{1/-}\text{Rag}^{2/-}\text{IL}2\text{rg}^{/-}\) (FRG) rats for PHH xenotransplantation. Indeed, all regular methods used in \(\text{Fah}^{-/-}\) or FRG mice to induce liver injury could not be applied during liver xenorepulation of human hepatocytes in FRG rats because of their extremely high mortality after NTBC withdrawal. A survival-assured liver injury preconditioning (SALIC) protocol was developed for achieving a robust xenorepulation of human hepatocytes in FRG rats. The rat model with humanized liver was characterized for its potential advantages in pharmacological studies and for the expansion of functional human hepatocytes in large quantities. In addition, the SALIC protocol for inducing chronic liver injury with assured survival of recipients might shed light on the transplantation of human hepatocytes in other large-sized species.

2. Results

2.1. \(\text{Fah}^{1/-}\text{Rag}^{2/-}\text{IL}2\text{rg}^{/-}\) Rats Develop Acute Liver Failure after NTBC Withdrawal

We generated severely immunodeficient \(\text{Rag}^{2/-}\text{IL}2\text{rg}^{/-}\) (RG) rats using the CRISPR/Cas9 system (Figures S1 and S2A, Supporting Information). Abnormal lymphoid development of RG rats was validated by histological analyses (Figure S2B, Supporting Information). Importantly, CD3\(^+\)CD45RA\(^-\) T cells, CD3\(^+\)CD45RA\(^-\) B cells, and CD3\(^+\)CD161\(^+\) NK cells were depleted in the spleen as shown by flow cytometry analyses (Figure S2C, Supporting Information). In addition, IgG, IgM, and IgA were undetectable in RG rats (Figure S2D–F, Supporting Information).

RG rats were crossed with \(\text{Fah}^{1/-}\) rats\(^\text{19}\) to breed into FRG rats. During a continuous process to feed NTBC in drinking water,
FRG rats could survive for more than 1.5 years (Figure 1A,B), providing a sufficient time span for studying liver xenorepulation and the following characterizations. After NTBC withdrawal, FRG rats developed acute liver failure, evidenced by elevated serum levels for ALT and AST as well as local massive necrosis in their liver (Figure 1C,D). Different from Fah−/− rats that developed liver cirrhosis after NTBC withdrawal,19 FRG rats only showed moderate liver fibrosis (Figure 1E). Notably, all FRG rats died within 4 weeks after NTBC withdrawal. Despite a faster liver failure, FRG rats died much faster than FRG mice, whose death usually occurred 4–8 weeks after NTBC withdrawal.2 FRG rats died much faster than FRG mice, whose death usually occurred 4–8 weeks after NTBC withdrawal. These findings suggested that NTBC withdrawal-induced liver injury was extremely harmful to FRG rats, which may hamper the manipulation process for hepatocyte transplantation and liver repopulation.

2.2. Characterization of the Xenotransplantation of Mouse Hepatocytes into the Livers of FRG Rats

FRG rats were characterized for the repopulation of transplanted hepatocytes. We first determined the number of hepatocytes required for liver repopulation. Syngeneic wild-type rat hepatocytes ranging from 0.5 to 10 million were intraportally transplanted into FRG rats at 6–10 weeks of age, and NTBC feeding was removed after transplantation. FRG rats receiving 0.5 million hepatocytes died within 1 month (Figure S3A, Supporting Information). When the number of transplanted hepatocytes increased to 2.5 million, accounting for ~1/500 of total rat hepatocytes, 54% of rat recipients survived liver failure-induced death and showed 78 ± 11% of liver repopulation 2 months after transplantation (Figure S3A–C, Supporting Information). Remarkably, a further increase in donor hepatocytes (5 or 10 million) did not significantly improve survival rate (Figure S3A, Supporting Information), although repopulation rates were increased slightly (Figure S3B,C, Supporting Information). Given the high repopulation rates and the comparable survival rates, transplantation with 2.5 million donor hepatocytes was selected in our following analyses.

It was reported that rat hepatocytes showed almost identical liver repopulation kinetics as mouse hepatocytes (MHs) in FRG recipient mice.23 To understand xenotransplantation in FRG rats, we first transplanted MHs into the liver. All FRG rats receiving 2.5 million MHs died within 3 weeks after NTBC withdrawal (Figure 2A,B). Small clusters of FAH+ donor hepatocytes were observed in livers of FRG recipient rats, proving the engraftment and repopulation of MHs but at relatively low levels (Figure S3D, Supporting Information). To improve...
Figure 2. FRG rats as a xeno-repopulation model for mouse hepatocytes. A) Schematic outline of mouse hepatocyte (MH) transplantation into the livers of FRG rats. After MH transplantation, NTBC was either permanently withdrawn from drinking water (w/o cycling) or repeatedly supplied dependent on the change in body weight. When over 15% body weight was lost, NTBC was transiently put on for 4 days (cycling $\Delta 15\%$ BW). B) Kaplan–Meier survival curve of MH-transplanted FRG rats with or without NTBC cycling (Cycling $\Delta 15\%$ BW). C) Serum ALT and AST levels in moribund FRG rats within 2 weeks after NTBC withdrawal (FRG w/o NTBC) and in MH-transplanted FRG rats with NTBC cycling for 8 weeks (MH-FRG cycling $\Delta 15\%$ BW), n = 4. D) The repopulation of MHs was analyzed by FAH staining in the FRG rat livers with NTBC cycling $\Delta 15\%$ BW 8 weeks after transplantation, and E) the repopulation rate (n = 4) was determined by FAH staining. Scale bar, 1000 and 50 μm (zoom in). F) FAH and HE staining of serial liver sections from MH-FRG rats 8 weeks after transplantation. M, mouse; R, rat. Scale bar, 100 μm. The data are shown as mean ± SD. **p < 0.01, ***p < 0.001, log-rank test for (B) and Student’s t test for (C).
xeno-repopulation efficiency, we performed NTBC cycling, a protocol previously used to maintain survivals of Fak−/− mice during liver repopulation. Briefly, NTBC treatment was restarted when the recipient body weight was reduced by 15%, a critical point at which most animals could not survive further body weight loss (NTBC cycling15%BW) (Figure 2A). Under NTBC cycling15%BW, 6 of 12 FRG rat recipients successfully survived to 8 weeks after transplantation (Figure 2B). Levels of serum ALT and AST were significantly reduced in survived FRG rat recipients (Figure 2C). As determined by immunofluorescent assay of FAH and whole slide imaging (see the Experimental Section), MHs repopulated 62 ± 11% of recipient livers (Figure 2D,E). Morbologically, repopulated MHs were similar with rat hepatocytes in recipient livers (Figure 2F). Together, these results indicated that robust liver xeno-repopulation from MHs could be successfully obtained in FRG rats. Overall, optimal control of the survival rate is the major issue for transplantation in FRG rats.

2.3. Establishment of Optimal Survival-Assured Liver Injury Preconditioning for the Expansion of Human Hepatocytes

Human hepatocyte transplantation was performed in FRG rats based on the conditioning protocol obtained from MH transplantation. After 2.5 million cryopreserved PHHs were intraportally transplanted, FRG rat recipients underwent NTBC cycling15%BW. Five of 10 FRG rat recipients died within the first month, and all other FRG rat recipients died within 4 months (Figure S4A, Supporting Information). To improve recipient survival, the NTBC cycling protocol was optimized when the body weight of FRG rat recipients was reduced by 10% (NTBC cycling10%BW, Figure 3A) instead of 15%. Under NTBC cycling10%BW, eight of nine FRG rat recipients transplanted with PHH successfully survived after 1 month. Three of nine FRG rat recipients further survived after 5 months (cycling10%BW vs cycling15%BW, p = 0.02) (Figure 3B) and showed a significant improvement in liver function (Figure S4B, Supporting Information). Human albumin (hALB) was secreted substantially to 0.8 ± 0.4 mg mL−1 5 months after PHH transplantation (Figure S4C, Supporting Information). Levels of PHH xeno-repopulation were 15 ± 11% as determined by the FAH immunofluorescence assay (Figure S4D, Supporting Information), which was far below the expected PHH repopulation efficiency (30%) for functional assays. Moreover, the high death rate (6/9) made it difficult to apply this protocol. Obviously, the NTBC cycling10%BW protocol should be further optimized to improve liver xeno-repopulation efficiency in FRG rats.

Liver injury is essential for the repopulation of transplanted PHHs. However, it should be controlled at a proper level without killing FRG rat recipients before robust repopulation of transplanted PHHs. When analyzing moribund FRG rats under NTBC cycling10%BW, we found that body weight loss did not change concomitantly with elevated ALT and AST levels, suggesting that body weight loss did not reliably reflect the severity of liver failure (Figure S4E, Supporting Information). We therefore decided to control chronic liver injury more precisely by manipulating NTBC concentrations and cycling intervals rather than monitoring body weight loss. Instead of full removal of NTBC, FRG rats were treated with reduced doses of NTBC to induce liver injury. The colony maintenance dose of NTBC (5 mg L−1) was taken as 100% NTBC. An NTBC treatment of 1% led to the mortality of FRG rats comparable to those with complete NTBC removal, whereas 10% NTBC treatment only caused mild liver injury (Figure S5A,B, Supporting Information). Notably, 4% NTBC (0.2 mg L−1) treatment induced chronic liver injury efficiently and extended the median survival time to 22 days (Figure S5A,B, Supporting Information), which almost doubled that of FRG rats with complete NTBC removal and provided an extended time window to manipulate NTBC cycling.

To maximize liver injury while keeping FRG rats alive, we determined the optimal duration of low-dose NTBC treatment in the NTBC cycling protocol (Figure S5C, Supporting Information). NTBC cycling with 4% NTBC for 9 days to induce liver injury followed by 100% NTBC for 4 days for recovery resulted in a mortality of 50% at around 40 days, which was too high for PHH transplantation (Figure S5D, Supporting Information). When FRG rats treated with 4% NTBC for 5 or 7 days during NTBC cycling, survival rates were increased to 2 months (Figure S5E, Supporting Information). Moreover, when livers from these rats were analyzed, 4% NTBC treatment for 7 days induced higher liver injury as manifested by increased fibrosis (Figure S5F, Supporting Information). NTBC cycling was finally determined using 4% NTBC for 7 days followed by 100% NTBC for 4 days (NTBC cycling with fixed treatment, NTBC cyclingFT).

Notably, around 3% of hepatocytes were Ki67 positive in FRG rats after treatment of NTBC cyclingFT, suggesting it created a regenerative microenvironment (Figure S5F, Supporting Information). To exploit the regenerative microenvironment only for transplanted hepatocytes, we blocked the proliferation of endogenous hepatocytes with retrorsine treatment. Retrorsine pretreatment before NTBC cyclingFT remarkably inhibited the proliferation of endogenous hepatocytes (Figure S5F, Supporting Information). Together, the combination of retrorsine pretreatment and NTBC cyclingFT was established as the SALIC protocol for liver xeno-repopulation of human hepatocytes.

2.4. Achievement of Robust Liver Xeno-Repopulation of Human Hepatocytes in FRG Rats

PHHs were transplanted into FRG rats following the SALIC protocol (Figure 3C). Remarkably, seven of eight FRG rat recipients survived after 5 months (Figure 3B). Survival rate significantly increased when the SALIC protocol was compared to NTBC cycling15%BW and NTBC cycling10%BW (p < 0.0001 and p = 0.02, respectively; Figure 3B). Meanwhile, there was no significant difference in survival curves between rats transplanted with two different PHHs (p = 0.61, Figure S6A, Supporting Information). Importantly, the level of hALB secretion continuously increased to an average of 1.7 ± 0.3 mg mL−1 in five of six survived FRG rat recipients after 7 months (Figure 3D). One recipient showed that hALB levels plateaued at 2700 μg mL−1, probably because of low engraftment of transplanted PHH since the beginning (Figure 3D). The five remaining rats with hALB levels >1 mg mL−1 were further characterized.

Macroscopic analyses indicated that humanized rat livers were normal in shape and showed similar liver/body weight ratios when compared with nontransplanted livers.
Supporting Information). Immunofluorescent staining of human-specific nuclei antigen (Figure S6C, Supporting Information) demonstrated a consistent level of liver xenorepopulation from human cells as high as 31 ± 4% (Figure 3E,F). Co-staining for human FAH, ALB, and AAT further confirmed the human origin of repopulated hepatocytes (Figure 3G and Figure S6D, Supporting Information). The immunofluorescent staining of hNuclei or FAH suggested the repopulation rate in FRG rats was comparable with that in FRG mice transplanted with the same donor PHHs (31 ± 4% vs 50 ± 31%; p = 0.2) (Figure 3F and Figure S6E, Supporting Information). Because a rat liver has roughly 1 billion hepatocytes, if engraftment efficiency of transplanted PHHs was estimated at 10%[23] it was calculated that the engrafted PHHs expanded around 1200 times up to 300 million in vivo. In addition, there was no significant difference in repopulation rates between rats transplanted with two different PHHs (15 ± 14% vs 32 ± 3%; p = 0.12). Overall, these data suggested the reproducibility of the SALIC regimen.

FAH human hepatocytes were completely integrated in rat liver parenchyma without disturbing the normal liver structure (Figure 3H). The repopulated human hepatocytes could be distinguished from rat hepatocytes by showing pale cytoplasm staining of eosin and increased accumulation of glycogen (Figure 3H and Figure S6F, Supporting Information). Remarkably, there were around 10% hALB+Ki67+ human hepatocytes at 7 months after transplantation, holding the potential to achieve even higher liver humanization (Figure 3I). It was noteworthy that no tumors originating from either human or rat hepatocytes were detected in humanized livers as determined by pathological analysis and AFP staining (Figure 3H and Figure S6G, Supporting Information).

Together, these findings indicated that a notable level of liver humanization was established in FRG rat recipients by SALIC. In following analyses, human-specific liver metabolism, in terms of transcriptome, zonation, and drug metabolism, were characterized in FRG rats of humanized liver.

2.5. Humanized Rat Liver Maintains the Transcriptome Features of Human Liver

The xenogeneic microenvironment in the liver of rodent species may influence the gene expression of repopulated human hepatocytes.[30] To evaluate whether repopulated human hepatocytes in FRG rats maintained the typical transcriptome of mature human hepatocytes, human-specific RNA-sequencing analysis was performed on liver homogenates from the humanized livers of FRG rats (see the Experimental Section). The humanized liver of FRG mouse[24] generated from the same donor hepatocytes was also used as a control. Human fetal liver cells (hFLCs)[27] were used as the control of immature hepatocytes. The expression profile analysis demonstrated humanized rat livers clustered closer to donor PHHs and humanized mouse livers than hFLCs (Figure 4A). Pearson’s correlation coefficient was further calculated to determine similarities between PHHs and humanized livers. Humanized rat livers showed a higher level of correlation to donor PHHs (r = 0.867) than to hFLCs (r = 0.669) (Figure 4B and Figure 5A, Supporting Information).

Humanized rat livers displayed significant enrichment in the expression of genes involved in hepatocyte functions by gene set enrichment analysis (GSEA; Figure 4C). Specifically, humanized rat livers maintained the gene expression of liver metabolism pathways (Figure 4D and Figure S7B,C, Supporting Information). RNA sequencing data of some metabolism genes of PHHs were further confirmed by quantitative polymerase chain reaction (qPCR) using human-specific primers, including ALB; phase 1 enzymes CYP1A4, CYP2A6, CYP2C9, and CYP2E1; phase II enzymes UGT2B7 and GSTA1; and transporters SLC22A1 and SLC01B1. These metabolism genes were expressed in humanized rat livers at levels comparable with those in PHHs (Figure 4E and Figure S7D, Supporting Information). By contrast, humanized rat livers did not show an expression of AFP, a marker of fetal liver cells, supporting the maintenance of a mature phenotype of PHHs after robust repopulation in FRG rats (Figure S7E, Supporting Information).

Intriguingly, whereas 86.2% of total genes were expressed similarly between PHH and humanized rat liver, 2209 genes showed differential expression (Figure S7F,G, Supporting Information). We explored the biological implications of the differentially expressed genes (DEGs) between humanized rat livers and PHHs using gene ontology analysis. The upregulated genes in humanized rat livers displayed enrichment in pathways related to the small molecule metabolism, lipid and steroid hormone biosynthesis, and cell cycle (Figure 4F). These upregulated metabolism pathways were also enriched in humanized mouse livers (Figure S7H, Supporting Information), suggesting the influence of xenogeneic microenvironment in vivo[26] or reflecting the difference between repopulated PHH and cryopreserved PHH. The upregulation of cell cycle genes was consistent with the
proliferative state of repopulated PHHs. On the other hand, the downregulated genes in humanized rat livers showed enrichment in pathways related to the hypoxia-inducible factor (HIF) pathway and the regulation of lipid storage (Figure 4F). The downregulation of VEGFa and VEGFβ expression in the HIF pathway might partially account for low vessel density in PHH-repopulated clones (Figures S7G and S8, Supporting Information). The increase of lipid biosynthesis and dysregulation of lipid storage were in line with slightly enhanced lipid accumulation of repopulated PHHs as shown by hematoxylin and eosin (HE) staining (Figure 3H). Collectively, these results indicated that humanized rat livers with over 30% chimerism largely retained the expression of mature human hepatocyte genes.

2.6. Human-Specific Metabolic Architecture Is Established in Humanized Rat Livers

Lobule zonation is the fundamental architecture of the liver.[28] Hepatocytes along the porto-central axis of the liver lobule show remarkable heterogeneity with respect to metabolic functions. Under such circumstance, the key metabolic enzymes are preferentially expressed in periportal or pericentral hepatocytes.[29] Previous studies revealed that human-specific liver zonation was formed in humanized mouse livers with essential human liver metabolism.[9] We investigated whether human-specific metabolism was successfully established in livers of FRG rats, featuring proper human liver zonation. Immunofluorescent assay validated the pericenter-specific expression of glutamine synthetase in repopulated human hepatocytes (Figure 5A). In addition, expressions of pericenter-specific phase I enzymes, CYP3A4 and CYP1A2, were only found in the repopulated human hepatocytes of pericentral regions by using human-specific immunofluorescent assay (Figure 5A). By contrast, portal-specific ARG1 showed an expression pattern restrictive to portal areas composed of repopulated human hepatocytes (Figure 5A). Furthermore, both ubiquitously expressed phase II enzyme UGT2B7 and transporter MRP2 were found in repopulated human hepatocytes along the liver lobule (Figure 5B). Such expression pattern was consistent with that in human liver lobules.

2.7. Human-Specific Drug Metabolism Is Established in Humanized Rat Liver

Human-specific drug metabolism was one of the most expected features of humanized livers of FRG rats. Based on previous studies[24–25] liver-humanized FRG rats with a serum level of hALB > 1 mg mL$^{-1}$ were used to prove this specific feature. Characterization of the metabolic activity of human-specific phase II enzyme UGT2B7 was chosen because it involves the metabolism for about one-third of all drugs presently used in the clinic.[30] Zidovudine (AZT), the first approved drug for HIV treatment,[31] was specifically used as a probe substrate for UGT2B7 activity in glucuronidation. In human liver, AZT is converted by UGT2B7 to AZT-5' glucuronide (GAZT)[32] (Figure 6A). By contrast, less than 10% of the administered dose of AZT was converted into GAZT in rat livers. To monitor the human-specific metabolism of orally administrated AZT, 200 μL of blood samples were collected for six time points (1.2 mL in total) at 0, 0.5, 1, 2, 4, and 8 h (Figure 6A), a volume not possible for mice. The area under the plasma concentration–time curve (AUC) of AZT and GAZT was measured (Figure 6B). The similarity between AUC$_{\text{h}}$ and AUC$_{\text{rat}}$ confirmed the sampling time points were sufficient to analyze pharmacokinetics (Table S1, Supporting Information). The peak concentration (C$_{\text{max}}$) of AZT showed no significant difference between liver-humanized rats and FRG rats (3060.8 ± 102.0 and 3196.4 ± 694.5 ng mL$^{-1}$, respectively; p = 0.7547) (Figure 6B and Table S1, Supporting Information). Notably, liver-humanized rats showed significantly increased C$_{\text{max}}$ of GAZT compared with the control group (725.1 ± 166.6 and 222.3 ± 32.9 ng mL$^{-1}$, respectively; p = 0.0068) (Figure 6B and Table S1, Supporting Information). Moreover, the AUC ratios of GAZT and AZT (GAZT/AZT) were 39 ± 16% and 6 ± 3% in humanized and control rats, respectively, demonstrating human-specific UGT2B7 activity in liver-humanized FRG rats (Figure 6C). Additionally, only rats with hALB levels > 1 mg mL$^{-1}$ showed significantly increased UGT2B7 activity, further suggesting the metabolic activity of UGT2B7 was highly correlated to chimerism (Figure 6D). Together, these data suggested that liver-humanized rats could be used as a model to reflect human-specific drug metabolism.

3. Discussion

Liver-humanized animals have become the state-of-the-art model systems to mimic both physiological and pathological features of human livers.[3,13] Liver humanization has been studied in several species, including mice, rats, and pigs, but it is only successfully accomplished in mice. Here, we reported the establishment of humanized liver in FRG rats, which will be favored in pharmacological studies.

More than four mouse models were successfully generated with efficient liver-humanization through either hepatotoxic transgene expression or gene knockout.[3,13] Among them, Fah knockout showed some extraordinary advantages, such as controllable liver injury and easiness in genetic manipulation, and thus became the main strategy for liver humanization in other animals.[14] Intriguingly, Fah–/– mice showed significant discrepancies in pathology when compared to Fah-deficient animals.
Figure 5. Liver zonation of metabolism in humanized rat liver. A) The liver zonation was determined by staining for human ALB, FAH, CYP3A4, CYP1A2, and ARG1. CV, central vein; PV, portal vein. Scale bar, 100 μm. B) The expression of phase II enzymes and transporters was representatively analyzed by staining for FAH, UGT2B7, and MRP2. Scale bar, 100 μm.

Moreover, previous findings suggested delayed repopulation kinetics of transplanted human hepatocytes in rats. In this study, we found that FRG rats were sensitive to NTBC withdrawal-induced liver injury and died faster compared with FRG mice. These features of FRG rats prevented a direct application of the precondition protocol used for FRG mice. We thus developed SALIC, which combined both retrorsine pretreatment and optimized NTBC cycling, to assure survival while maintaining the regenerative microenvironment induced by chronic liver injury. Under such optimized precondition, the engrafted human hepatocytes maintained a continuous proliferation up to >7 months after xenotransplantation, the underlying mechanism of which is not yet understood. Notably, SALIC improved both the survival of FRG rats and liver xenorepobulation rate without detectable liver tumorigenesis. By contrast, long-term (>6 months) NTBC cycling would induce liver cancers in FRG mice. It is possible that the treatment of low-dose NTBC induced low levels of liver injury and limited the accumulations of mutagenic molecules. It is conceivable that transient retrorsine pretreatment might also contribute to undetectable tumorigenesis.

Repopulation kinetics of transplanted hepatocytes is largely influenced by liver size. The precondition learned from rats might shed light on hepatocyte transplantation in species of large sizes. Humanized livers generated in pigs were proposed as alternative organs for clinical liver transplantation, given the similarity between pig livers and human livers in size and anatomy. Fah-deficient rat and pig both developed acute liver failure after NTBC withdrawal and were sensitive to retrorsine-mediated inhibition of hepatocyte proliferation. It may be worth testing whether the principle of SALIC could be applied to liver humanization in Fah pigs. Furthermore, it would be interesting to propose SALIC as a useful reference for hepatocyte transplantation in human patients.

Predicting both human-specific drug metabolite profiles and pharmacokinetics in vivo is important for estimating drug efficacy and toxicity. For drugs such as AZT, only primates were chosen for toxicity studies because they had a metabolic profile (i.e., GAZT formation) similar to that of humans. Notably, liver-humanized rats display human-specific drug metabolism in terms of metabolite profiles and pharmacokinetics, which can be an alternative model to primates for such toxicity analysis.
Despite the significantly high GAZT formation in liver-humanized rats, the pharmacokinetics of AZT was similar between liver-humanized rats and FRG control rats. It was possible that AZT was eliminated by multiple mechanisms, e.g., the important contribution of renal clearance. Technically, it demands sequential blood sampling from one tested animal to complete the pharmacokinetic study. We showed that one liver-humanized rat could provide at least 1.2 mL of blood sample without adverse effects on physiology. It is impossible to collect such volume of blood samples from mice, as it approximately equals the whole blood volume for one mouse. It is apparent that liver-humanized rats have unique advantages in testing drugs requiring sequential blood samplings.

Expanding PHHs and maintaining their mature phenotype at the same time remains challenging in vitro. In vivo expansion via humanized liver in animals is an alternative solution. We showed that repopulated human hepatocytes in FRG rats maintained a mature gene expression profile, providing a new system to expand human hepatocytes. Rats are ten times larger than mice, and one rat is capable of producing at least 1 billion human hepatocytes if fully repopulated. It would be possible to isolate large quantities of fully functional human hepatocytes from FRG rats to meet most applications, including high-throughput drug screening and application in liver assist devices. In this study, an expansion of at least 1200 times had been achieved in FRG rats based on an initial engraftment of 0.25 million human hepatocytes (engraftment efficiency estimated at 10%) and a final harvest of about 300 million after 30% repopulation of rat livers. By contrast, an ≈150-fold expansion of human hepatocytes was generally achieved in FRG mice. Despite their advantages, it took as long as 7 months to achieve 30% human chimerism in FRG rat livers, which apparently required further improvements in the efficiency of liver humanization. It was previously reported that the transplantation of an increased number of human hepatocytes reproducibly facilitated high human chimerism. In addition, it was reported that 70–80% of transplanted donor hepatocytes were cleared by the resident macrophage in liver. Compared with FRG mice on the C57BL/6J strain, liver humanization was established faster in those on the NOD strain, in which the signal regulatory protein alpha (Sirpα) binds to CD47 in human hepatocytes and thus decreased the phagocytosis of human hepatocytes by mouse macrophages via CD47-Sirpα interaction (the so-called “don’t eat me” signal). The enhanced level of liver humanization may be also achieved in FRG rats with human Sirpα knock-in. With these future improvements, humanized livers in FRG rats would serve...
as a model for studies on pharmacology and liver diseases and as an efficient tool for in vivo expansion of human hepatocytes.

4. Experimental Section

Generation of Fah−/− Rag2−/− IL2rg−/− Rats: The Rag2 and IL2rg double mutant rats were generated by microinjection of sgRNA and Cas9 mRNA into wild-type (WT) SD rat zygotes. Following crossing with Fah−/− rats, Fah−/− Rag2−/− IL2rg−/− (FRG) rats were generated and fed with drinking water containing 5 mg L−1 NTBC (synthesized by Capot Chemical, China). All animal experiments were performed according to protocols approved by the animal care and use committee at the Shanghai Institute of Biochemistry and Cell Biology and the University of Tsukuba.

Xenotransplantation of Human Hepatocytes in FRG Rats: The cryopreserved PHHs from four individuals (Lot: JFC, TVR, QIE, and XLJ) were purchased from Celsis In Vitro Technologies (Baltimore, MD). In the pilot experiments, 6 days before cell transplantation, NTBC concentration in drinking water for FRG rats was first reduced to 2.5 mg L−1 for 3 days and was then totally withdrawn for another 3 days. Then, 2.5 × 106 PHHs in 500 μL phosphate-buffered saline (PBS) were transplanted through the portal vein into the liver of FRG rats. NTBC was transiently put on for 4 days when rats lost over 10% of their body weights (NTBC cycling1010BW). Rats were sacrificed 5 months later. In the SALIC protocol, 30 mg kg−1 retorsine (Sigma) was intraperitoneally injected to FRG rats 2 weeks before transplantation. NTBC cycling with fixed treatment (NTBC cycling9) was carried out 1 week before transplantation and lasted until the end of the experiment. Briefly, the rats were repeatedly administered with 0.2 mg L−1 NTBC for 7 days to induce injury followed by 5 mg L−1 NTBC for 4 days to allow recovery. Rats were sacrificed 7 months later.

Histology, Immunohistochemistry, and Immunofluorescence: These were performed according to the standard procedures as previously described.24 See the Supporting Information for details.

RNA Sequencing Data Process: All sequencing reads from RNA-seq were mapped to the human reference genome (hg38) using hisat2-2.10. The number of biological and technical replicates were harvested and stained using FAH or hNuclei antibody to detect repopulated donor hepatocytes. Whole slide imaging was further conducted to minimize the potential bias caused by high-magnification views. The FAH+ or hNuclei+ areas were measured using ImageJ. Repopulation rate was calculated as: FAH+ or hNuclei+ area/total liver lobe area scanned × 100%.

Data Resources: The accession number for the RNA-seq data reported in this paper is GEO: GSE162862 (www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE162862).

Supporting Information

Supporting Information is available from the Wiley Online Library or from the author.

Acknowledgements

The authors are thankful to Dr. Xin Wang for critical suggestions during manuscript preparation and Dr. Baqing Wu, Xiaorui Zhang, the Animal Core Facility at SIBCB, Yuko Jinzenji, Dr. Kenichi Iwasaki, Dr. Yoshio Shimizu, Daisuke Sako, and the Laboratory Animal Resource Center at the University of Tsukuba for animal care. This project was supported by the National Key Research and Development Project (2020YFA0112503), the “Strategic Priority Research Program” of the Chinese Academy of Sciences (CAS, XDA16020201), the National Natural Science Foundation of China (NSFC) (82070638, 32070797, 81700621, 31930030, 32052023), Japan Society for the Promotion of Science (JSPS) KAKENHI (JP18H02866), National Key Research and Development Project (2019YFA0110802 to D.L.), MEXT (Ministry of Education, Culture, Sports, Science & Technology in Japan) scholarship, the Youth Innovation Promotion Association CAS, and the SA-SIBS Scholarship Program.

Conflict of Interest

The authors declare no conflict of interest.

Author Contributions

L.Z., J.-Y.G., and Y.-W.Z. contributed equally to this work. L.H. and Y.-W.Z. conceived and supervised the study. L.Z. and J.-Y.G. designed and performed most of the experiments; Z.S. and C.W. assisted in the characterization of humanized rats; B.W., L.Z., and X.M. analyzed the RNA-seq data; Z.P. and G.P. performed the analysis of UGT2B7 activity in vivo; D.L. and L.Z., J.-Y.G., and Y.-W.Z. contributed equally to this work. L.H. and Y.-W.Z. supplied experimental materials and resources; and L.Z., J.-Y.G., Y.-W.Z., and L.H. analyzed the data and wrote the manuscript.

Data Availability Statement

The data that support the findings of this study are openly available in GEO: GSE162862 at www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE162862.

Keywords

bioreactor, humanized liver, liver xeno-repopulation, pharmacological study
M. Prieto-Vila, K. Hosaka, A. Takeuchi, Y. Saito, T. Ochiya, *Elife* 2019, 8, e47313; c) H. Hu, H. Gehart, B. Artegiani, L. O.-I. C. F. Dekkers, O. Basak, J. van Es, S. M. Chuva de Sousa Lopes, H. Begthel, J. Korving, M. van den Born, C. Zou, C. Quirk, L. Chiriboga, C. M. Rice, S. Ma, A. Rios, P. J. Peters, Y. P. de Jong, H. Clevers, *Cell* 2018, 175, 1591; d) Y. Kim, K. Kang, S. B. Lee, D. Seo, S. Yoon, S. J. Kim, K. Jang, Y. K. Jung, K. G. Lee, V. M. Factor, J. Jeong, D. Choi, *J. Hepatol.* 2019, 70, 97.

[44] B. Joseph, H. Malhi, K. K. Bhargava, C. J. Palestro, R. S. McCuskey, S. Gupta, *Gastroenterology* 2002, 123, 1677.